Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
1 Juli 2026
Herbert Smith Freehills Kramer advises Ampol on its $1.165 billion acquisition of EG Australia
HSF Kramer has advised Ampol Limited on its $1.165 billion acquisition of EG Group Australia Pty Ltd and EG AsiaPac Holdings Pty Ltd (together, EG …
30 Juni 2026
Hiswara Bunjamin & Tandjung advises joint sponsors, overall coordinators and underwriters on the secondary listing of Hong Kong Depositary Receipts of Merdeka Gold Resources
Leading Indonesian law firm Hiswara Bunjamin & Tandjung (HBT) has advised CITIC Securities (Hong Kong) Limited and UBS Securities Hong Kong Limited …
30 Juni 2026
Herbert Smith Freehills Kramer advises Xunlong Sci-tech on its Hong Kong IPO
Leading global law firm Herbert Smith Freehills Kramer has advised on Hangzhou Qiandaohu Xunlong Sci-tech Co., Ltd. (06715.HK)’s listing on the Main …